Moderna stock has fallen over the past four years, but shares got a boost on positive comments about AI. Is MRNA stock a buy ...

SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at ...

Adar Poonawalla, CEO, Serum Institute of India talks to Arijit Barman about a range of issues including the impact of Trump’s ...

President Donald Trump talked up a joint venture investing up to $500 billion for infrastructure tied to AI by a new ...

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

Netflix earnings after the bell drive focus in tech stocks. Dow and S&P climb as optimism over trade policy fuels market ...

"Today’s court decision will only grant Ursula von der Leyen a temporary respite from trial," Belgian lobbyist Frederic Baldan stressed ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near future ...

We recently compiled a list of the 10 Best High-Yield Dividend Stocks To Invest In. In this article, we are going to take a ...

Selective stock-picking and conviction drove HB Biotech’s strong 2024 performance. Read our insights on navigating today’s ...